PARP inhibitors in ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/27/suppl_1/i40/19447068/mdw094.pdf
Reference29 articles.
1. Platinum combination chemotherapy versus platinum monotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis of randomised trials using individual patients data (IPD);Raja;Ann Oncol,2012
2. Experience with bevacizumab in the management of epithelial ovarian cancer;Burger;J Clin Oncol,2007
3. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J Clin Oncol,2012
4. (ADP-ribose)n participates in DNA excision repair;Durkacz;Nature,1980
5. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase;Bryant;Nature,2005
Cited by 107 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cancers de l’ovaire. Des nouvelles molécules pour chaque type histologique ou moléculaire, une avancée vers plus de guérison ?;Bulletin de l'Académie Nationale de Médecine;2024-08
2. Proteomic landscaping of high‐grade serous ovarian carcinoma identifies stearoyl‐CoA desaturase 5 as a potential predictive biomarker for poly(ADP‐ribose) polymerase inhibitor response;Clinical and Translational Medicine;2024-05
3. Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer;International Journal of Molecular Sciences;2024-03-09
4. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer;Seminars in Cancer Biology;2023-11
5. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor;Human Pathology;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3